FDA Targets Misleading Drug Ads, Shifting Strategy Could Make Ads Less Feasible
The FDA has launched a crackdown on misleading drug ads, sending thousands of warning letters and about 100 cease-and-desist orders.
FDA Commissioner Marty Makary described DTC ads as a 'public health crisis' and the industry's advertising practices are being reevaluated.
The strategy includes closing loopholes like the 'adequate provision' rule, which could make advertising less feasible due to increased transparency and enforcement.